Trial Profile
The Effect of TRADJENTA (LINAGLIPTIN) on Inflammation, Oxidative Stress and Insulin Resistance in Obese Type 2 Diabetes Subjects
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 23 Feb 2023
Price :
$35
*
At a glance
- Drugs Linagliptin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Biomarker; Pharmacodynamics
- Acronyms 1971
- 02 Feb 2022 Status changed from active, no longer recruiting to completed.
- 02 Nov 2017 Planned End Date changed from 1 Aug 2016 to 1 May 2018.
- 02 Nov 2017 Planned primary completion date changed from 1 Jul 2016 to 1 Feb 2018.